Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

RTTNews | Před 640 dny
Stocktwits
Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

(RTTNews) - Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had annual sales of $609 million as of July 2023, according to IQVIA data.

Teva's generic equivalent of Forteo (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device. Teriparatide injection is indicated to treat osteoporosis among certain women and men.

The market availability of the drug-device combination product in the U.S. is expected in the coming weeks.

Antares, a wholly owned subsidiary of Halozyme Therapeutics, Inc., and Teva are parties to an exclusive license, development and supply agreement for Teriparatide auto injector product that Teva markets in the EU and will market in the U.S.

Značky : TEVA
Stocktwits
read more
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews | Před 502 dny
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | Před 649 dny
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the second quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | Před 747 dny
Teva Pharma Reaffirms FY23 Outlook - Update

Teva Pharma Reaffirms FY23 Outlook - Update

While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews | Před 831 dny
Teva Recalls FENTANYL Buccal Tablets CII

Teva Recalls FENTANYL Buccal Tablets CII

Teva Pharmaceuticals USA is recalling specific lots of various strengths of FENTANYL Buccal Tablets CII to the consumer level citing a labeling error, the U.S. Food and Drug Administration said. The recall has been initiated because safety updates were omitted in the product insert/medication guide that are provided with these recalled lots.
RTTNews | Před 841 dny
Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

Teva Pharmaceutical Industries Ltd. (TEVA) announced Friday the appointment of Dr. Eric Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, New Jersey.
RTTNews | Před 1144 dny
Australian Market Trims Early Losses In Mid-market

Australian Market Trims Early Losses In Mid-market

The Australian stock market is trimming its early losses in mid-market trading on Tuesday, extending the losses in the previous session, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling to near the 8,900 level, with weakness in mining and energy stocks partially offset by gains in financial stocks.
RTTNews | Před 1 h 10 min
Nástroje
Ekonomický kalendář
Otevírací hodiny trhu
Úrokové sazby
Kalendář svátků
Forexový trh
Forex volatilita
Korelace Forexu
Novinky na Forexu
Analýza forexu
COT údaje
Likvidita
Forex kalkulačky
Forex Tepelná mapa
Tepelná mapa indikátorů
Komunita
Komunita
Systémy
Nejpopulárnější systémy
Strategie
Soutěže
Forexové grafy
Forexový sentiment
Indikátor Outlook
Recenze
Brokeři
Proprietární obchodní firmy
Služby VPS
Poskytovatelé signálu
Služby programování EA
Partnerské programy
Služby PAMM Brokera
Služby slevového programu
Obchodní platformy
Odborní poradci
Kryptoburzy
Kurzy obchodování
Brokeři
Forex Spready
Nabídky Forex brokerů
Swapy Forex brokerů
Objem brokera Forexu
Propagační akce Forex Brokera
Tisková Zpráva
Platforma
Miniaplikace
Funkce
API
RSS
Stock Portfolio
Affiliate Software
Rozšířené grafy
Podpora
Časté dotazy
Pomoc
Kontaktuj nás
Nahlásit chybu!
O nás
Blog
& copy; 2025 Myfxbook Ltd. Všechna práva vyhrazena.
UPOZORNĚNÍ NA VYSOKÉ RIZIKO: Obchodování s devizami přináší vysokou úroveň rizika, které nemusí být vhodné pro všechny investory. Páka vytváří další rizika a ztráty. Než se rozhodnete obchodovat s devizami, důkladně zvažte své investiční cíle, úroveň zkušeností a toleranci vůči riziku. Můžete přijít o část nebo všechny své počáteční investice. Neinvestujte peníze, které si nemůžete dovolit ztratit. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Všechny údaje a informace jsou poskytovány "tak, jak jsou". pouze pro informační účely a nejsou určeny pro obchodní účely nebo rady. Výkonnost v minulosti neznamená výkonnost v budoucnosti.